Atossa Therapeutics (ATOS) Non-Current Deffered Revenue (2014 - 2015)
Atossa Therapeutics (ATOS) posted quarterly Non-Current Deffered Revenue of $5688.0 for Q3 2015, down 43.23% quarter-over-quarter from $10019.0 in Q2 2015.
Atossa Therapeutics (ATOS) Non-Current Deffered Revenue (2014 - 2015) Analysis & Trends
Atossa Therapeutics (ATOS) has reported Non-Current Deffered Revenue for 2 consecutive years, with $5688.0 the latest figure, recorded in Q3 2015.
- In Q3 2015, Non-Current Deffered Revenue changed N/A year-over-year to $5688.0; the TTM figure through Sep 2015 stood at $5688.0 (changed N/A YoY), while the FY2014 annual figure was $2483.0, changed N/A from the prior year.
- Non-Current Deffered Revenue eased to $5688.0 in Q3 2015 per ATOS's latest filing, from $10019.0 in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $10019.0 in Q2 2015 and bottomed at $2483.0 in Q4 2014.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 147.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Atossa Therapeutics | 22.63 Mn | 22.63 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2015 | 5,688.00 |
| Jun 30, 2015 | 10,019.00 |
| Mar 31, 2015 | 7,227.00 |
| Dec 31, 2014 | 2,483.00 |